People: Albany Molecular Research Inc (AMRI.O)

AMRI.O on Nasdaq

22.18USD
19 Sep 2014
Price Change (% chg)

$-0.71 (-3.10%)
Prev Close
$22.89
Open
$23.10
Day's High
$23.11
Day's Low
$21.81
Volume
886,903
Avg. Vol
389,269
52-wk High
$23.31
52-wk Low
$9.71

Search Stocks

Summary

Name Age Since Current Position

Thomas D' Ambra

58 2013 Non-Executive Chairman of the Board

William Marth

59 2014 President, Chief Executive Officer, Director

Michael Nolan

49 2012 Chief Financial Officer, Vice President, Treasurer

George Svokos

56 2014 Senior Vice President - Sales, General Manager - API

Steven Hagen

53 2012 Senior Vice President - Manufacturing and Pharmaceuticals

Michael Luther

57 2013 Senior Vice President - Discovery Services

Lori Henderson

52 2011 Vice President, General Counsel, Secretary

Una Ryan

72 2010 Lead Independent Director

Veronica Jordan

63 2006 Independent Director

Gabriel Leung

52 2010 Independent Director

Kevin O' Connor

59 2000 Independent Director

Arthur Roth

2003 Independent Director

Biographies

Name Description

Thomas D' Ambra

Dr. Thomas E. D' Ambra, Ph.D. has been re-designated as Non-Executive Chairman of the Board of Albany Molecular Research Inc., with effective December 31, 2013. He co-founded the Company in 1991 and has served as Company's Chairman of the Board and Chief Executive Officer since inception. Dr. D’Ambra was appointed the additional title of President in February 2003, a position he also held from 1991 – 1998. Prior to co-founding the Company, Dr. D’Ambra served as the Vice President, Chemistry and co-founder of Coromed, Inc., a traditional development contract research organization, from 1989 to 1991 and Group Leader and Senior Research Chemist with Sterling Winthrop, Inc., a pharmaceutical company, from 1982 to 1989. Dr. D’Ambra holds a B.A. degree in chemistry from the College of the Holy Cross and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology.

William Marth

Mr. William S. Marth has been re-designated as President, Chief Executive Officer, Director of Albany Molecular Research, Inc., with effective January 1, 2014. Mr. Marth joined AMRI as a member of the Board of Directors in June 2012. Mr. Marth was formerly President and Chief Executive Officer of Teva Americas, retiring from Teva in 2012. He serves as a senior advisor to Teva through the end of 2013. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and prior to that as President and Chief Executive Officer of Teva USA. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA. Mr. Marth earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University. He is a licensed pharmacist and serves on various other boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins’ Project RESTORE. In addition, Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.

Michael Nolan

Mr. Michael M. Nolan has been appointed as Chief Financial Officer, Vice President, Treasurer of Albany Molecular Research Inc., effective September 17, 2012. Mr. Nolan was most recently Vice President, Finance, Financial Planning and Analysis at the Delaware North Companies, headquartered in Buffalo, N.Y. From 2009 through early 2012, Mr. Nolan was Vice President, Finance, Analytical Instruments Group at Thermo Fisher Scientific, Inc. where he was responsible for the global financial operations of a portfolio with revenue of $3 billion operating across three divisions with 15 business units, 41 plant sites and 9,700 employees. Prior to Thermo Fisher Scientific, Mr. Nolan held positions of increasing responsibility at ALCAN, which was later acquired by Rio Tinto Plc. While at Rio Tinto Plc., Mr. Nolan was accountable for the integration of 13 global ALCAN and Rio Tinto Plc. functions, including legal, company secretarial, business development and all finance functions including both the corporate and business teams. Mr. Nolan began his career in 1989 at E.I. du Pont de Nemours Company and received his MBA from The University of Windsor and a B.A. in Economics from The University of Western Ontario.

George Svokos

Mr. George Svokos is the Senior Vice President - Sales, General Manager - API of Albany Molecular Research Inc. Before coming to AMRI, Mr. Svokos had been with Teva Pharmaceuticals Industries Ltd. since 1979. Most recently, he was Senior Vice President of Product and Portfolio Selection, and Business Development, responsible for strategic planning, portfolio selection, new product introductions and business development. From 2011 to 2012, Mr. Svokos was Senior Vice President, US Technical Operations, responsible for strategic planning, manufacturing, supply chain, regulatory and legal compliance, and safety, for eleven U.S. dosage form manufacturing facilities, as well as supply of branded and generic products to the U.S. market from overseas plants in Europe, the Middle East, China and India. Before this role, he served as Executive Vice President of Commercial Operations, Teva API, leading the global sales and marketing of Teva's API division, including a global sales force, with multibillion-dollar sales. Mr. Svokos is the Senior Vice President of the Drug, Chemical & Associated Technologies Association (DCAT) and will become President next year. Mr. Svokos earned a Master's degree in Business Administration from the University of Missouri and a Bachelor's of Science degree in Chemical Engineering from Columbia University.

Steven Hagen

Dr. Steven R. Hagen, Ph.D. has been appointed as Senior Vice President - Manufacturing and Pharmaceuticals of Albany Molecular Research Inc., effective 22 October 2012. Dr. Hagen joined AMRI in 2005 as senior director of analytical quality services and has risen to positions of increasing responsibility. In 2006, Dr. Hagen was promoted to vice president for quality and analytical chemistry and was responsible for Analytical Chemistry, Quality Assurance and Regulatory Affairs for all AMRI locations. In 2008, Dr. Hagen was promoted to vice president of pharmaceutical development and manufacturing. Prior to AMRI, he spent more than 10 years at Pfizer in positions of increasing responsibility culminating in director of analytical research and development at Pfizer's Global Research and Development Division. Before Pfizer, he managed the analytical activities at Ribi ImmunoChem Research, Inc. in support of R&D, production and quality control. Dr. Hagen earned a Ph.D. in biochemistry and a Master's degree in botany, both from the University of Idaho, as well as a B.A. in biology from Lawrence University.

Michael Luther

Dr. Michael A. Luther, Ph.D. has been appointed as Senior Vice President - Discovery Services of Albany Molecular Research, Inc., effective October 28, 2013. Dr. Luther was most recently Corporate Vice President of Global Discovery Research Services at Charles River Laboratories, from August 2012 through September 2013, where he served as the general manager of the firm's discovery business unit, including developing and implementing strategic and operating plans. Prior to his role at Charles River, from March 2009 through August 2012, he was President and a member of the Board of Directors of the David H. Murdock Research Institute in Kannapolis, North Carolina where he led and directed all activities of the institute, which included applied R&D activities that facilitate and accelerate discovery to proof of principle and early product development in areas of human health. Prior to this, from November 2006 through March 2009 he held the position of Vice President and Site Head at Merck Frosst at their Montreal, Canada site, focused on the delivery of Phase I candidates from target to clinic for novel therapeutics in respiratory and metabolic disorders. Prior to this, from 1991 through 2006 he held positions of increasing responsibility at GlaxoSmithKline, culminating in his appointment as Vice President, High Throughput Biology. Dr. Luther earned his Ph.D. in biophysical chemistry from St. Louis University School of Medicine; an M.B.A. from Duke University, Fuqua School of Business; and a B.Sc. in biology and chemistry from North Carolina State University. Dr. Luther has authored numerous scientific papers and serves on several Boards of Directors for both academic and industry trade organizations, including the Center for Tropical and Emerging Global Diseases and the College of Life Sciences Research Foundation, North Carolina State University.

Lori Henderson

Ms. Lori M. Henderson, Esq. is Vice President, General Counsel, Secretary of Albany Molecular Research Inc. She joined AMRI in 2011 and is responsible for all of AMRI’s legal activities for the Company’s locations worldwide, including the United States, Europe and Asia. She also serves as the corporate secretary. From 2008 to 2010, she served as general counsel, corporate secretary and chief administrative officer for Rand Worldwide, Inc. where she oversaw the legal, human resource and IT departments of this technology company. Ms. Henderson was part of the management team that led the transaction between Rand Worldwide and Avatech Solutions Inc. From 1999 through 2008 she held increasing positions of responsibility at Moldflow Corporation and most recently was general counsel, corporate secretary and chief administrative officer for Moldflow Corporation, a company operating in the CAD/CAE business with global operations. At Moldflow, Ms. Henderson was responsible for the legal, human resources and IT functions at the Company, and was part of the management team that completed the sale of Moldflow to Autodesk in June 2008. Ms. Henderson also served as corporate counsel and secretary at C.P. Clare Corporation and prior to that was an associate at Goodwin Procter LLP, specializing in corporate transactions. Ms. Henderson holds a B.A. from Gordon College and a J.D. from George Washington University.

Una Ryan

Dr. Una S. Ryan Ph.D., OBE, is Lead Independent Director of Albany Molecular Research Inc., since October 2006. She is currently President of Diagnostics for All, a non-profit focused on low-cost and easy-to-use diagnostics for the developing world. Previously, she was President and CEO of Waltham Technologies, Inc. a company in the Clean Water-Clean Energy business. Concurrently, she holds the position of research professor of medicine at Boston University School of Medicine. Prior to joining Waltham, she was President and CEO of AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) and also a member of its Board of Directors, 1993 to 2007. Prior to AVANT, she was director of Health Sciences at Monsanto Company, 1990 to 1993. Before that, she held a number of positions in academia, including research professor of surgery at Washington University School of Medicine in St. Louis, 1990 to 1994; and professor of medicine at the University of Miami School of Medicine, 1972 to 1989. Dr. Ryan graduated from England’s Bristol University, with B.Sc. degrees in Zoology, Chemistry, and Microbiology. In 2009 she received an Honorary D.Sc. from Bristol University. She received a Ph.D. from Cambridge University. Dr. Ryan has served on several private company boards and industry trade organizations, including the board of BIO, and is past chair of the Massachusetts Biotechnology Council. In 2002, she was awarded the Order of the British Empire (O.B.E.) for her work to foster and promote biotechnology.

Veronica Jordan

Dr. Veronica G. H. Jordan, Ph.D. is an Independent Director of Albany Molecular Research Inc., since October 2006. Dr. Jordan is an independent consultant providing senior management experience to companies developing novel healthcare products and services. Previously she served as president, chief executive officer and board member of Medelle Corporation, a medical device company in the women’s health area. Prior to joining Medelle, Dr. Jordan served 14 years, 1987 – 2001, as Senior Vice President and before that Vice President at Parexel International Corporation, a global contract pharmaceutical outsourcing organization that provides clinical research, medical marketing and consulting services. Dr. Jordan worked at Biogen Incorporated (now Biogen Idec), 1981 – 1987, as product manager and was ultimately promoted to director of marketing and business development. In 1979, Dr. Jordan began her industry career in the R&D labs at Baxter International after earning a B.Sc. in Biochemistry from Cambridge University and a Ph.D. in Biochemistry/Cell Biology from Oxford University, and completing a postdoctoral research fellowship at the Dana Farber Cancer Institute.

Gabriel Leung

Mr. Gabriel S. Leung is an Independent Director of Albany Molecular Research Inc., since November 2010. In August 2011, Mr. Leung was named Executive Vice Chairman of the board of Novocure, Ltd., a medical device company pioneering the fourth cancer treatment modality. From 2003 through 2010 Mr. Leung held executive positions at OSI Pharmaceuticals, most recently as executive vice president and president of the Pharmaceutical Business at OSI. While at OSI he was responsible for the entire oncology business unit, including Research and Development, Commercial, Medical Affairs and Business Development. Mr. Leung was instrumental in the record-setting launch of oncology drug Tarceva by OSI in 2004 and the acquisition of OSI by Astellas in 2010. Prior to OSI, Mr. Leung held positions at Pharmacia, most recently as Group VP, Global Prescription Business & Head, Global Oncology Franchise; and Bristol-Myers Squibb, most recently as Senior Director, US Oncology Marketing and Sterling Drug Inc. Mr. Leung has served as an advisor to the National Cancer Institute and has served for over ten years under former President George H.W. Bush as an active member of C-Change, a national initiative aiming to eliminate cancer as a public health concern. He holds a B.S. in Pharmacy from the University of Texas at Austin and a M.S. in Pharmacy from University of Wisconsin-Madison.

Kevin O' Connor

Mr. Kevin O' Connor is an Independent Director of Albany Molecular Research Inc., since March 2000. Mr. O’Connor has served as Chief Executive Officer of Tech Valley Communications, a telecommunications company, since July 2000. Mr. O’Connor previously served as the President of the Center for Economic Growth, Inc., a business-sponsored economic development organization, from February 1992 through July 2000. Mr. O’Connor also served as a Deputy Commissioner for the New York State Department of Economic Development from September 1987 to February 1992, as a Program Associate for the New York State Governor’s Office from July 1984 to September 1987 and held various positions in the New York State Division of the Budget and the New York State Department of Health from January 1980 to July 1984. Mr. O’Connor also serves as a director of several private companies and non-profit organizations. Mr. O’Connor holds a B.A. degree in history and a Masters degree in public administration from the State University of New York College in Brockport.

Arthur Roth

Mr. Arthur J. Roth, CPA, is an Independent Director of Albany Molecular Research Inc., since October 2003. Mr. Roth previously served as commissioner of the New York State Department of Taxation and Finance from 1999 to 2003. Prior to his appointment as Commissioner, Mr. Roth was Deputy Commissioner for Operations, New York State Department of Taxation and Finance from 1996 until 1999. Mr. Roth was a senior consulting director with Coopers and Lybrand from 1992 to 1996 and a founder and managing director of Roth Nobis & Company, an accounting firm serving the manufacturing and service industries, from 1968 to 1992. Mr. Roth serves as a director for MVP Healthcare and also serves as director for several non-profit companies. Mr. Roth served on the Board of Directors and as the Chair of the Audit Committee of First Albany Capital Inc. from October 2003 until August 2006. Mr. Roth is a certified public accountant and holds a B.A. degree from Syracuse University.

Basic Compensation

Name Fiscal Year Total

Thomas D' Ambra

4,043,140

William Marth

--

Michael Nolan

789,972

George Svokos

--

Steven Hagen

594,038

Michael Luther

610,629

Lori Henderson

631,837

Una Ryan

--

Veronica Jordan

--

Gabriel Leung

--

Kevin O' Connor

--

Arthur Roth

--
As Of 30 Dec 2013

Options Compensation

Search Stocks